dc.contributor.author | Redondo-Anton, Jennifer | |
dc.contributor.author | Gomez Fontela, Miguel | |
dc.contributor.author | Notario, Laura | |
dc.contributor.author | Torres-Ruiz Raul, Torres-Ruiz Raul | |
dc.contributor.author | Rodríguez-Perales, Sandra | |
dc.contributor.author | Lorente, Elena | |
dc.contributor.author | Lauzurica, Pilar | |
dc.date.accessioned | 2021-02-26T10:07:38Z | |
dc.date.available | 2021-02-26T10:07:38Z | |
dc.date.issued | 2020-10-27 | |
dc.identifier.citation | Front Genet. 2020 Oct 27;11:552949. | es_ES |
dc.identifier.issn | 1664-8021 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/12006 | |
dc.description.abstract | The CD69 gene encodes a C-type lectin glycoprotein with immune regulatory properties which is expressed on the cell surfaces of all activated hematopoietic cells. CD69 activation kinetics differ by developmental stage, cell linage and activating conditions, and these differences have been attributed to the participation of complex gene regulatory networks. An evolutionarily conserved regulatory element, CNS2, located 4kb upstream of the CD69 gene transcriptional start site, has been proposed as the major candidate governing the gene transcriptional activation program. To investigate the function of human CNS2, we studied the effect of its endogenous elimination via CRISPR-Cas9 on CD69 protein and mRNA expression levels in various immune cell lines. Even when the entire promoter region was maintained, CNS2-/- cells did not express CD69, thus indicating that CNS2 has promoter-like characteristics. However, like enhancers, inverted CNS2 sustained transcription, although at a diminished levels, thereby suggesting that it has dual promoter and enhancer functions. Episomal luciferase assays further suggested that both functions are combined within the CNS2 regulatory element. In addition, CNS2 directs its own bidirectional transcription into two different enhancer-derived RNAs molecules (eRNAs) which are transcribed from two independent transcriptional start sites in opposite directions. This eRNA transcription is dependent on only the enhancer sequence itself, because in the absence of the CD69 promoter, sufficient RNA polymerase II levels are maintained at CNS2 to drive eRNA expression. Here, we describe a regulatory element with overlapping promoter and enhancer functions, which is essential for CD69 gene transcriptional regulation. | es_ES |
dc.description.sponsorship | The study was supported by the Instituto de Salud Carlos III MPY1346/16, MPY127/19 and Comunidad de Madrid S2018/BAA-4480 Biopieltec-CM. JR-A was supported by AESI MPY1346/16. MGF was supported by a pre-doctoral fellowship (FPU, FPU 15/05605) from the Spanish Ministry of Education, Culture and Sports (MECD). SR-P and RT-R were supported by grants from the Spanish National Research and Development Plan, Instituto de Salud Carlos III, and FEDER (PI17/02303 and DTS19/00111) and AEI/MICIU EXPLORA Project BIO2017-91272-EXP. RT-R was also supported by a postdoctoral fellowship from the Asociación Española Contra el Cáncer (AECC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Frontiers Media | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | CD69 | es_ES |
dc.subject | Enhancer | es_ES |
dc.subject | Enhancer-derived RNA (eRNA) | es_ES |
dc.subject | Immune regulation | es_ES |
dc.subject | Promoter | es_ES |
dc.subject | Transcriptional regulation. | es_ES |
dc.title | Functional Characterization of a Dual Enhancer/Promoter Regulatory Element Leading Human CD69 Expression. | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 33193627 | es_ES |
dc.format.volume | 11 | es_ES |
dc.format.page | 552949 | es_ES |
dc.identifier.doi | 10.3389/fgene.2020.552949. eCollection 2020 | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | |
dc.contributor.funder | Comunidad de Madrid (España) | |
dc.contributor.funder | Ministerio de Educación, Cultura y Deporte (España) | |
dc.contributor.funder | Asociación Española Contra el Cáncer | |
dc.description.peerreviewed | Sí | es_ES |
dc.relation.publisherversion | https://doi.org/10.3389/fgene.2020.552949 | es_ES |
dc.identifier.journal | Frontiers in Genetics | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/MPY1346/16 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/MPY127/19 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/S2018/BAA-4480 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/FPU 15/05605 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/PI17/02303 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/DTS19/00111 | es_ES |
dc.rights.accessRights | open access | es_ES |